contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


new-number-of-shares-and-votes-in-medivir-ab-publ

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Medivir develops drugs with a focus on cancer diseases where the medical needs are great. The drug candidates are directed towards indication areas where available treatment methods are limited or absent. Medivir focuses on the development of fostrox, a drug candidate that has been designed to selectively treat cancer cells in the liver. The company was founded in 1988 and is headquartered in Huddinge.

Medivir

The number of shares and votes in Medivir AB (publ) (the “Company”) increased during December 2025 as a result of the rights issue resolved by the board of directors on 8 October 2025, and approved...

<div class="mfn-preamble"><p><strong>The number of shares and votes in Medivir AB (publ) (the “Company”) increased during December 2025 as a result of the rights issue resolved by the board of directors on 8 October 2025, and approved by the extraordinary general meeting on 10 November 2025.</strong></p></div><div class="mfn-body"><p>As of 30 December 2025, the total number of shares in the Company amounts to 451,121,383 shares, of which 448,671,220 ordinary shares and 2,450,163 class C shares (previously 114,617,968 shares, of which 112,167,805 ordinary shares and 2,450,163 class C shares). All shares in the Company carry 448,916,236 votes. One ordinary share entitles the holder to one (1) vote, and one class C share entitles the holder to one tenth (1/10) of a vote. All class C shares are held by the Company.<br>&nbsp;<br>As of 30 December 2025, the share capital amounts to SEK 67,668,207.45 (previously SEK 17,192,695.20<a rel="noopener" href="http://#_ftn1">[1]</a>).</p><p>&nbsp;<em>The English text is an unofficial translation of the original Swedish text. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.</em></p></div><div class="mfn-footer mfn-contacts mfn-9771c060c61c"><p><strong class="mfn-heading-1">For additional information, please contact;</strong><br>Jens Lindberg<br>Chief Executive Officer<br>Medivir AB<br>M: +46 72 531 11 17<br>Email: <a rel="noopener" href="mailto:jens.lindberg@medivir.com">jens.lindberg@medivir.com</a><br>&nbsp;<br>Magnus Christensen<br>Chief Financial Officer<br>Medivir AB<br>M: +46 73 125 06 20<br> Email: <a rel="noopener" href="mailto:Magnus.Christensen@medivir.com">Magnus.Christensen@medivir.com</a></p></div><div class="mfn-footer mfn-about mfn-1cf93d4e26af"><p><strong class="mfn-heading-1">About Medivir</strong><br>Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is focusing on the development of fostroxacitabine bralpamide (fostrox), a drug candidate designed to selectively treat cancer cells in the liver and to minimize side effects. Collaborations and partnerships are important parts of Medivir’s business model, and the drug development is conducted either by Medivir or in partnership. Medivir’s share (ticker: MVIR) is listed on Nasdaq Stockholm’s Small Cap list. <a rel="noopener" href="http://www.medivir.com">www.medivir.com</a>.&nbsp;</p><p><a rel="noopener" href="http://#_ftnref1">[1]</a> At the Extraordinary General Meeting on 10 November 2025, it was resolved to reduce the Company's share capital by SEK 40,116,288.80. After the reduction of the share capital, which was registered with the Swedish Companies Registration Office in December 2025, the Company's share capital amounted to SEK 17,192,695.20.</p></div><div class="mfn-footer mfn-regulatory mfn-regulatory-lhfi"><p><em>This information is information that Medivir is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2025-12-30 08:30 CET.</em></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a rel="noopener" href="https://storage.mfn.se/5a2866d7-133a-43b6-91d4-4bcd8990dd8a/press-release-pdf.pdf" class="mfn-generated mfn-primary">Press Release (PDF)</a></p></div>

New number of shares and votes in Medivir AB (publ)

Faron Pharmaceuticals

Herantis Pharma

Mendus

Probabilities of success in drug development

Financial Key Ratios: EV/EBIT, EV/EBITA, EV/EBITDA, and EV/Sales

Solar Foods

Solar Foods is planning a listing on the Nasdaq First North Growth Market Finland marketplace

Return on capital (ROE, ROI, ROIC, RONIC)

The DuPont formula helps understand the dynamics of value creation